Synthetic Biologics, Inc. (SYN)

NYSEAMERICAN: SYN · IEX Real-Time Price · USD
1.53
+0.01 (0.66%)
Aug 16, 2022 11:33 AM EDT - Market open
0.66%
Market Cap 24.24M
Revenue (ttm) n/a
Net Income (ttm) -17.78M
Shares Out 15.84M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jul 25, 2022
Volume 37,652
Open 1.54
Previous Close 1.52
Day's Range 1.51 - 1.56
52-Week Range 1.35 - 5.60
Beta 1.33
Analysts Buy
Price Target 16.58 (+983.7%)
Earnings Date Aug 11, 2022

About SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; ... [Read more...]

Industry Biotechnology
IPO Date Jun 26, 2006
CEO Steven Shallcross
Employees 16
Stock Exchange NYSEAMERICAN
Ticker Symbol SYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 16.58, which is an increase of 983.66% from the latest price.

Price Target
$16.58
(983.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform-

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high...

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Fin...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high...

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics d...

Synthetic Biologics Announces Reverse Stock Split

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high...

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral p...

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascendin...

-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers-

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Fina...

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high ...

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and extension into oncology Scientific Advisory Board o...

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Ant...

- VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy-

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 ...

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)-

Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences-

Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig...

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology-

Synthetic Biologics Completes Acquisition of VCN Biosciences

- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration -

Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial...

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig...

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unme...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U....

ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unme...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unm...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic V...

ROCKVILLE, Md. , Dec. 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high un...

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be He...

ROCKVILLE, Md., Nov. 3, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal A...

ROCKVILLE, Md., Oct. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...